Aripiprazole and Resistant Postpartum Depression
|ClinicalTrials.gov Identifier: NCT01386086|
Recruitment Status : Completed
First Posted : June 30, 2011
Last Update Posted : March 17, 2016
|Condition or disease||Intervention/treatment||Phase|
|Postpartum Depression||Drug: aripiprazole||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Augmentation Therapy of Resistant Postpartum Depression With Aripiprazole|
|Study Start Date :||June 2011|
|Actual Primary Completion Date :||November 2013|
|Actual Study Completion Date :||November 2013|
aripiprazole used adjunctively to antidepressants in patients with resistant postpartum depression
The starting dose of aripiprazole will be 2 mg and the dose adjusted to a maximum of 15 daily
- Montgomery Asberg Depression Rating Scale [ Time Frame: 6 weeks ]To assess the effectiveness of the addition of aripiprazole in the treatment of resistant postpartum depression as measured by the change in mean scores on the Montgomery Asberg Depression Rating Scale between baseline and the study termination endpoint.
- Udvalg for Kliniske Undersogelser Scale [ Time Frame: 6 weeks ]To assess the tolerability of aripirazole in women with resistant postpartum depression as assessed by the Udvalg for Kliniske Undersogelser Scale.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01386086
|Regional Mental Health Care|
|London, Ontario, Canada, N6A4H1|
|Principal Investigator:||Verinder Sharma, MBBS||University of Western Ontario, Canada|